Roman Butler Fullerton & Co. acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the third quarter, Holdings Channel.com reports. The institutional investor acquired 3,989 shares of the biopharmaceutical company’s stock, valued at approximately $489,000.
A number of other institutional investors also recently added to or reduced their stakes in HALO. Mather Group LLC. increased its position in Halozyme Therapeutics by 48.9% during the 3rd quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 136 shares during the period. CoreCap Advisors LLC raised its stake in shares of Halozyme Therapeutics by 98.0% during the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 150 shares in the last quarter. Fifth Third Wealth Advisors LLC raised its stake in shares of Halozyme Therapeutics by 3.5% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 4,515 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 151 shares in the last quarter. Twin Capital Management Inc. lifted its holdings in shares of Halozyme Therapeutics by 1.4% in the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 161 shares during the period. Finally, First Citizens Bank & Trust Co. lifted its holdings in shares of Halozyme Therapeutics by 2.0% in the 1st quarter. First Citizens Bank & Trust Co. now owns 9,088 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 175 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.
Wall Street Analysts Forecast Growth
HALO has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price target on Halozyme Therapeutics from $70.00 to $78.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. TD Cowen raised their target price on Halozyme Therapeutics from $105.00 to $130.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Finally, Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $99.55.
Insider Activity
In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $109.40, for a total value of $2,188,000.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at $83,995,132. This represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 125,852 shares of company stock worth $13,538,046. Company insiders own 2.50% of the company’s stock.
Halozyme Therapeutics Stock Up 1.2%
HALO stock opened at $130.03 on Thursday. The company has a market cap of $14.76 billion, a P/E ratio of 38.82, a P/E/G ratio of 0.47 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $130.24. The company’s 50-day moving average price is $112.74 and its 200 day moving average price is $82.87. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period in the prior year, the business posted $1.54 earnings per share. The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current fiscal year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.
Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.
Read More
- Five stocks we like better than Halozyme Therapeutics
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
